Some surgical procedures result in prolonged, moderate-to-severe postoperative pain that is often difficult to control. Continuous peripheral nerve blocks are often effective analgesics, but are usually limited to a few days due to infection risk, and bring a host of possible complications, such as catheter dislocation and leakage, infusion pump malfunction, and the burden of carrying a local anesthetic reservoir \[[@B1]\]. One possible alternative analgesic modality is cryoneurolysis: using extremely low temperatures to reversibly ablate nerves, with a subsequent analgesia duration measured in weeks or months \[[@B2]\]. The technique has been in use for decades to treat chronic pain, but new advances in cryoneurolysis equipment and ultrasound training raise the possibility of using cryoneurolysis to replace continuous peripheral nerve blocks to treat acute postoperative pain \[[@B3]\]. This report is the first to describe the use of a single preoperative administration of ultrasound-guided percutaneous cryoneurolysis to provide multiple weeks of analgesia following shoulder rotator cuff repair and total knee arthroplasty in five patients.

Case Report
===========

Five patients undergoing orthopedic surgery of the shoulder (n = 2) and knee (n = 3) were offered, and consented to, preoperative administration of ultrasound-guided percutaneous cryoneurolysis for postoperative analgesia. The university\'s Institutional Review Board (University of California San Diego, San Diego, CA, USA) waives review requirements for case reports and short series, but all patients provided verbal consent for publication of these case reports. Additionally, all patients provided written informed consent for the cryoneurolysis procedures themselves, including with respect to the potential risks of cryoablation (unrelated to this report). Patients were positioned supine (knee) or prone with the chest supported on pillows and ipsilateral arm hanging over the side of the gurney (shoulder). American Society of Anesthesiologist standard monitors were used and the cryoprobe entry site was prepared with chlorhexidine gluconate.

A portable ultrasound (SonoSite M-Turbo, Bothell, WA, USA) and 13--6 MHz linear ultrasound transducer (HFL38; SonoSite) within a sterile sleeve were used to image the target nerves in a short-axis (cross sectional) view: the suprascapular nerve just superior to the suprascapular notch (shoulder) \[[@B4]\] or the infrapatellar branch of the saphenous nerve distal to its origin from the femoral nerve (knee) \[[@B5],[@B6]\]. A 20 gauge (G) angiocatheter was inserted through a lidocaine 1% (with epinephrine 1 : 200,000 for hemostasis) skin wheal immediately caudal to the transducer, and lidocaine 2% (1 ml) was deposited adjacent to the target nerve under ultrasound guidance. If accurate angiocatheter positioning was confirmed by sensory changes within the distribution of the target nerve occurring within 15 min, the stylet of the angiocatheter was withdrawn to allow insertion of the cryoneurolysis probe.

All procedures were executed using a 5.5-cm, 22-G, single-use cryoneurolysis probe (Smart Tip; Myoscience, Freemont, CA, USA) inserted under ultrasound guidance through the angiocatheter because the probe\'s closed tip is somewhat blunt \[[@B3]\]. A portable, handheld cryoablation device (Iovera Focused Cold Therapy; Myoscience Freemont, CA, USA)) was used to deliver nitrous oxide (N~2~O) through the center of the probe, using two cycles of 3-min freezing to −70℃, separated by a 2-min defrost ([Fig. 1](#F1){ref-type="fig"}). No patient reported discomfort during the cryoneurolysis itself, likely due to the previously injected lidocaine. A general anesthetic was administered for the surgical procedure.

All five patients experienced excellent postoperative analgesia with pain scores consistently \< 2 on a 0--10 numeric rating scale, and required significantly less opioid for a decreased period of time relative to historic controls \[[@B7],[@B8]\]. For the shoulder rotator cuff repair patients, there was full return of motor function by approximately 2--3 weeks following the original procedure. For patients having knee surgery, no gross motor deficit was noted, relative to historic controls, and skin sensation returned within 4 months. There was no adverse event related to the cryoneurolysis.

Discussion
==========

The cases discussed here suggest that cryoneurolysis (also known as "cryoanalgesia" or "cryoneuroanalgesia") may be a viable alternative to treating prolonged postoperative pain in a select cohort of patients (possibly particularly beneficial in patients at high risk for persistent post-surgical pain) \[[@B9],[@B10]\]. While cryoneurolysis has been used for decades to provide relief from chronic nerve pain \[[@B11]\], it was not until the 1980s that cryoneurolysis was applied to surgically exposed nerves to provide postoperative analgesia \[[@B12]\]. Probe technology advances have enabled percutaneous insertion and reports of its use treating chronic pain increased subsequently \[[@B2],[@B13]\], with a single retrospective report describing use to treat an acute pain state \[[@B14]\]. However, the advent of ultrasound guidance now enables extremely precise application to virtually any peripheral nerve \[[@B3]\]. The present report is, to our knowledge, the first to describe the preoperative use of ultrasound-guided percutaneous cryoneurolysis to provide multiple weeks of postoperative analgesia.

A modern cryoneurolytic probe creates extremely cold temperatures by passing a gas down the shaft at high pressure and through a small opening into a closed tip at low pressure, resulting in absorption of heat due to the Joule-Thomson effect ([Fig. 2](#F2){ref-type="fig"}) \[[@B3]\]. The gas is evacuated through an internal tube within the shaft so that no gas makes contact with, or remains within, the patient. An ice ball forms at the tip of the probe, inducing Wallerian degeneration distal to the point of ablation and resulting in a complete conduction block. Importantly, the endo-, peri-, and epineurium remain intact, allowing neural regrowth distally at 1--2 mm/day without the risk of neuroma formation. Block duration is dependent on multiple factors, such as the distance from the ablation to the terminal nerve ending, surrounding tissue temperature, and nerve diameter. The result is that the duration of analgesia is highly variable and often unpredictable, but is usually measured in weeks or months. Whether block duration could be better controlled by altering factors such as the freeze and/or thaw duration, or number of freeze-thaw cycles, requires further research.

Contraindications include Raynaud\'s syndrome, cryoglobulinemia, cold urticaria, bleeding disorders, localized infection, and anticoagulation. Risks include depigmentation, hyperpigmentation, alopecia in the hairline, and "frostbite" of the skin if the ice ball encompasses the dermis, as well as bruising and bleeding. Three clinical trials involving cryoneurolysis of intercostal nerves through thoracotomy incisions reported an increased risk of postoperative neuropathic pain, while many others found no such association \[[@B12]\].

The main limiting factors regarding the use of cryoneurolysis to treat postoperative pain are the complete sensory and motor block combined with the prolonged and often unpredictable duration of action. Prolonged sensory and/or motor blockade may not be desirable or safe in many circumstances. Specific acute pain applications (nerves) possibly amenable to cryoneurolysis are total shoulder arthroplasty and rotator cuff repair (suprascapular nerve), total knee arthroplasty and anterior cruciate ligament repair (infrapatellar branch of the saphenous nerve and anterior femoral cutaneous nerve), rib fractures and thoracotomy (intercostal), herniorrhaphy (intercostal/ilioinguinal), tonsillectomy (glossopharyngeal), iliac crest bone grafts (superior cluneal and/or subcostal nerves), and amputations and burns (any involved terminal nerve). Importantly, high-quality randomized, controlled clinical trials are necessary to gauge the benefit-to-risk ratio and optimize techniques/equipment prior to widespread adoption of perioperative cryoneurolysis, and informed consent should include the potential risk of neuropathic pain, at least until this issue has been resolved \[[@B12]\]. Nevertheless, the cases presented in this report demonstrate the possibility of applying ultrasound-guided percutaneous cryoneurolysis to provide analgesia following surgical procedures.
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